Qianjiang Yongan Pharmaceutical Co Ltd Asset Resilience Ratio
Qianjiang Yongan Pharmaceutical Co Ltd asset resilience ratio. Qianjiang Yongan Pharmaceutical Co Ltd (002365) has an Asset Resilience Ratio of 30.38% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Qianjiang Yongan Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Qianjiang Yongan Pharmaceutical Co Ltd (2014–2024)
Asset resilience ratio of Qianjiang Yongan Pharmaceutical Co Ltd from 2014 to 2024. This chart shows how Qianjiang Yongan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Qianjiang Yongan Pharmaceutical Co Ltd (002365) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Qianjiang Yongan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 002365 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥687.31 Million | 30.38% |
| Total Liquid Assets | CN¥687.31 Million | 30.38% |
Asset Resilience Insights
- Very High Liquidity: Qianjiang Yongan Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 30.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Qianjiang Yongan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Qianjiang Yongan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Qianjiang Yongan Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2014–2024)
Qianjiang Yongan Pharmaceutical Co Ltd asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for Qianjiang Yongan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.00% | CN¥600.16 Million ≈ $87.82 Million |
CN¥2.31 Billion ≈ $337.82 Million |
-0.85pp |
| 2023-12-31 | 26.85% | CN¥630.10 Million ≈ $92.20 Million |
CN¥2.35 Billion ≈ $343.46 Million |
+3.85pp |
| 2022-12-31 | 23.00% | CN¥557.50 Million ≈ $81.58 Million |
CN¥2.42 Billion ≈ $354.73 Million |
+3.14pp |
| 2021-12-31 | 19.86% | CN¥454.02 Million ≈ $66.44 Million |
CN¥2.29 Billion ≈ $334.50 Million |
-9.44pp |
| 2020-12-31 | 29.31% | CN¥634.10 Million ≈ $92.79 Million |
CN¥2.16 Billion ≈ $316.62 Million |
+9.14pp |
| 2019-12-31 | 20.16% | CN¥384.71 Million ≈ $56.29 Million |
CN¥1.91 Billion ≈ $279.18 Million |
+18.37pp |
| 2018-12-31 | 1.80% | CN¥34.70 Million ≈ $5.08 Million |
CN¥1.93 Billion ≈ $282.28 Million |
+0.70pp |
| 2017-12-31 | 1.10% | CN¥17.33 Million ≈ $2.54 Million |
CN¥1.58 Billion ≈ $231.19 Million |
-0.19pp |
| 2016-12-31 | 1.28% | CN¥16.33 Million ≈ $2.39 Million |
CN¥1.27 Billion ≈ $186.33 Million |
-23.07pp |
| 2015-12-31 | 24.36% | CN¥293.00 Million ≈ $42.88 Million |
CN¥1.20 Billion ≈ $176.04 Million |
+0.85pp |
| 2014-12-31 | 23.50% | CN¥279.00 Million ≈ $40.83 Million |
CN¥1.19 Billion ≈ $173.70 Million |
-- |
About Qianjiang Yongan Pharmaceutical Co Ltd
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmace… Read more